Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14263447 | 0.87 | TRPV1 (0.63) | CACNA1HKDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL14263465 | 0.81 | CACNA1H (0.65) | CACNA1HTRPV1 | |
| SCHEMBL14263483 | 0.80 | CACNA1H (0.84) | CACNA1HTRPV1 | |
| SCHEMBL8214513 | 0.80 | KDM4E (0.60) | CACNA1HKDM4EALDH1A1HSD17B10POLB | |
| SCHEMBL8213176 | 0.79 | TRPV1 (0.77) | CACNA1HTRPV1 | |
| SCHEMBL14263423 | 0.79 | TRPV1 (0.77) | CACNA1HTRPV1 | |
| SCHEMBL8214078 | 0.76 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL8210087 | 0.76 | CACNA1H (0.91) | CACNA1HALDH1A1HSD17B10TSHR | |
| SCHEMBL8212424 | 0.75 | CACNA1H (0.52) | CACNA1HTRPV1 | |
| SCHEMBL14263421 | 0.75 | CACNA1H (1.00) | CACNA1HTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-27 | — | — | US | disclosed |
| WO-2008033465-A1 | AZETIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076750-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, CES1, ZDHHC20 | CACNA1H 2829/4885KDM4E 445/4885ALDH1A1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.